Loading...
•
Mar 31, 2021
Dynavax Q1 2021 Earnings Report
Dynavax reported strong first quarter results driven by CpG 1018 adjuvant business and HEPLISAV-B market share growth.
Key Takeaways
Dynavax announced first quarter 2021 financial results with a total revenue of $83.3 million. The company's growth was driven by strong execution in the CpG 1018 adjuvant business and HEPLISAV-B market share growth.
Total revenue for the first quarter of 2021 was $83.3 million.
HEPLISAV-B net product revenue was $8.3 million in the first quarter of 2021.
CpG 1018 net product revenue was $74.6 million in the first quarter of 2021.
Net income for the first quarter of 2021 was $0.9 million.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...